Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model

Kimberley T Lee; Hailey W Bulls; Aasha I Hoogland; Brian W James; Claudia B Colon-Echevarria; Heather S L Jim

doi:10.3390/cancers16142571

Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model

Cancers (Basel). 2024 Jul 18;16(14):2571. doi: 10.3390/cancers16142571.

Authors

Kimberley T Lee¹, Hailey W Bulls², Aasha I Hoogland³, Brian W James⁴, Claudia B Colon-Echevarria⁵, Heather S L Jim³

Affiliations

¹ Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
² Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
³ Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
⁴ Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA.
⁵ Department of Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Abstract

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating symptom experienced by cancer survivors. Despite the burden of CIPN-related symptoms, interventions remain limited.

Objectives: This narrative review seeks to propose a framework for CIPN predisposing, precipitating, and perpetuating factors (3Ps), which will provide a foundation for future research and clinical interventions aimed at mitigating CIPN-related symptoms and morbidity.

Methods: A comprehensive literature search was performed using PubMed, guided by keywords related to "chemotherapy-induced peripheral neuropathy." Studies were limited to those with full text available in English.

Results: Predisposing factors outlined in this framework, such as older age and comorbid conditions, can be used to identify patients who have a higher risk of developing CIPN. The major precipitating factor of CIPN is the delivery of chemotherapy to peripheral nerves, which may be mitigated via cryotherapy or compression therapy during chemotherapy. Perpetuating factors can offer insight into psychological, cognitive, and behavioral modifications that could be treatment targets for CIPN management.

Conclusion: The proposed 3P model can guide the development of effective interventions for CIPN by suggesting modifiable psychological and behavioral treatment targets that may mitigate the impact of CIPN for cancer patients.

Keywords: cancer survivorship; chemotherapy-induced peripheral neuropathy; theoretical model.

Publication types

Review

Grants and funding

Dr. Lee’s time was supported by the National Cancer Institute of the National Institutes of Health (NIH) under Award Number K08CA279076-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Bulls’ time was financially supported by an institutional K award at the University of Pittsburgh (NIH KL2 TR001856 [PI: Rubio]) and the National Cancer Institute [K08CA263317]. Dr. Colon-Echevarria’s time was supported by the National Cancer Institute [U54CA163068 and U54CA163071].